Lorenzo Bertani

38PUBLICATIONS
142CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Rheumatology and arthritisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Environmental epidemiologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Sep 10, 2026
Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

|Feb 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Franco Scaldaferri, Federica Di Vincenzo, Marina Aloi

|Nov 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Giammarco Mocci, Antonio Tursi, Franco Scaldaferri

|Oct 24, 2025
The Impact of E-Cigarettes and Heat-Not-Burn Tobacco on Postoperative Recurrence of Crohn's Disease: A Multicenter International Study.

Tommaso Lorenzo Parigi, Olga Maria Nardone, Maria Lisa

|Sep 07, 2025
When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.

Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa

|Mar 27, 2025
Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn's Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study.

Alessandro Massano, Edoardo Vincenzo Savarino, Simone Saibeni

Pageof 7

Frequent Collaborators

10 joint publications

Edoardo Vincenzo Savarino

8 joint publications

Davide Giuseppe Ribaldone

5 joint publications

Massimo Bellini

5 joint publications

Alessandro Armuzzi